Recreational Cannabis Sales are Projected to Surpass Medical Sector | Financial Buzz

Recreational Cannabis Sales are Projected to Surpass Medical Sector

Recent data has signaled that the recreational sector of the cannabis market is growing at a faster rate than the medical segment. Projections indicate that recreational sales are expected to overtake medical sales as the proliferation of legalization continues. According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and the data suggests that industry is expected to reach USD 65 Billion by 2023. Additionally, due to widespread legalization, particularly in the U.S. for recreational use, the global industry is expected to accelerate the market at a robust 37% CAGR throughout the forecast period.

Colorado’s legal marijuana market hit a milestone of USD 6 Billion in sales at the end of 2018 since legalizing adult-use back in 2014, according to a report by Marijuana Business Daily. The report highlights that since 2016, recreational sales have continued to climb, while medical sales have declined sharply. Data showed that in 2018 alone medical cannabis sales fell 20% year-over-year from USD 416 Million to USD 332 Million. Meanwhile, recreational cannabis sales increased by 11% from USD 1 Billion to USD 1.2 Billion from 2017 to 2018.

Colorado’s medical segment reported its record high sales of USD 445 Million in 2016 but has continued to decline since then. Compared to the medical sector, the adult-use market is seeing strong growth each year as recreational sales have increased from USD 303 Million in 2014 to USD 1.2 Billion, representing a 296% increase.

Other states such as California and Nevada are also seeing similar trends as their recreational market sales are starting to overtake the medical segment. Even emerging markets are also seeing the same trend as well. During the U.S. mid-term elections, Michigan voters legalized cannabis for recreational use, with the ruling expected to go in effect by 2020. Marijuana Business Daily forecasts that recreational sales are expected to generate sales between USD 1.4 Billion and USD 1.7 Billion, making it one of the largest markets in the U.S, which currently has 10 states and the District of Columbia that have legalized cannabis entirely.

Among some of the emerging states, Massachusetts has come into the spotlight. Recreational sales in Massachusetts totaled USD 9.3 Million during its first four weeks of operation in December. Oregon delivered USD 14 Million in sales during its first month, but compared to Massachusetts, Oregon had 320 operational dispensaries while Massachusetts only had two.

The first two dispensaries in Massachusetts were averaging approximately USD 2.3 Million in sales per week when they opened to the public. Since then, the state has opened 48 more dispensaries for both medical and recreational cannabis. However, the state still remains a small market when compared to the larger West Coast states.

CLS Holdings USA, Inc. (OTCQB: CLSH) (CSE: CLSH) entered into Massachusetts’ market early on by locking up its acquisition of In Good Health in January. In Good Health is one of the eleven original applicants awarded the Certificate of Registration from the Department of Public Health and was the second to open in the state. The dispensary is located 25 miles south of Boston and operates as a medical dispensary, serving 18,000 patients.

While Colorado, California, and Nevada markets are much more matured than Massachusetts, the cannabis industry is still in its infancy stage nationally. As legalization continues to spread, other states will enter into the marketplace.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For cls holdings usa inc. financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: